Nonprescription/OTC: FDA Warning Letter to Macau-Union Pharmaceutical Limited, 2026-05-29
Letter issued · posted to fda.gov .
Subject as published: Nonprescription/OTC
TL;DR
At a glance: FDA issued a Warning Letter to Macau-Union Pharmaceutical Limited on 2026-05-29 citing: Nonprescription/OTC. Full letter: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/macau-union-pharmaceutical-limited-724506-05292026
Argus analysis
Macau-Union Pharmaceutical Limited (MARCS-CMS 724506, FEI 3011219786) received an FDA Warning Letter dated May 29, 2026 from the Center for Drug Evaluation and Research (CDER). The letter cites: Nonprescription/OTC. FDA posts Warning Letters to fda.gov after an internal review period; this one was made public on June 9, 2026.
Nonprescription/OTC letters typically cite the relevant OTC monograph under 21 CFR Part 330 (or the newer OTC monograph order process under the CARES Act) alongside 21 USC 352 misbranding provisions. Common findings involve active ingredients, dosing, or labeling claims that fall outside the applicable monograph's permitted conditions.
FDA Warning Letters typically specify a 15-working-day response window for the recipient to detail corrective actions. Compliance teams at peer companies in the same general compliance category commonly use a newly published letter as a prompt to re-check their own procedures against the same citation, and to watch fda.gov for a close-out letter confirming the cited firm's corrective action was accepted — or, absent one, for escalation to import alert, injunction, or product seizure.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
FDA Warning Letters are administratively non-binding but signal that recurring non-compliance may escalate to injunction, seizure, import alert, or Application Integrity Policy invocation.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Macau-Union Pharmaceutical Limited MARCS-CMS 724506 — May 29, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: Via Electronic Mail - Return Receipt Requested Product: Drugs Recipient: Recipient Name Mr. Kin Va Choi Recipient Title General Manager Macau-Union Pharmaceutical Limited 3 - 3A Rua Cinco Do Bairro Da Areia Preta Room B 1/F, Industrial Veng Fong Macao SAR China Issuing Office: Center for Drug Evaluation and Research (CDER) United States Warning Letter 320-26-83 May 29, 2026 Dear Mr. Choi: The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Macau-Union Pharmaceutical Limited, FEI 3011219786, at 3-3A Rua Cinco Do Bairro Da Areia Preta, Room B 1/F, Industrial Veng Fong, from December 15 to 17, 2025. This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). In addition, “Bamboo Pharmacy® Mobility penetrating muscle & joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a), 331(d). Additionally, these products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under section 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below. We reviewed your February 2, 2026, response to our Form FDA 483 in detail. CGMP Violations During our inspection, our investigators observed specific violations including, but not limited to, the following. 1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release, and for each batch of drug product required to be free of objectionable microorganisms, appropriate laboratory testing, as necessary (21 CFR 211.165(a) and 211.165(b)). Your firm did not adequately test your over-the-counter (OTC) drug products prior to release and distribution to the U.S. market. Specifically, your firm failed to test the identity and strength of each active ingredient before releasing the drug products. Your firm also failed to perform adequate microbiological testing on each batch of your drug products prior to release. You con…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- When did FDA issue the warning letter to Macau-Union Pharmaceutical Limited?
- FDA issued the letter (MARCS-CMS 724506) on 2026-05-29 and posted it publicly on fda.gov on 2026-06-09.
- Is the FDA warning letter to Macau-Union Pharmaceutical Limited publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/macau-union-pharmaceutical-limited-724506-05292026.
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a Warning Letter warning letter?
- FDA Warning Letters are administratively non-binding but signal that recurring non-compliance may escalate to injunction, seizure, import alert, or Application Integrity Policy invocation.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Nonprescription/OTC: FDA Warning Letter to Macau-Union Pharmaceutical Limited, 2026-05-29. Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-macau-union-pharmaceutical-limited-2026-05-29-warning-letter
"Nonprescription/OTC: FDA Warning Letter to Macau-Union Pharmaceutical Limited, 2026-05-29." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-macau-union-pharmaceutical-limited-2026-05-29-warning-letter.
Argus HQ Research. "Nonprescription/OTC: FDA Warning Letter to Macau-Union Pharmaceutical Limited, 2026-05-29." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/fda/warning-letter/fda-wl-macau-union-pharmaceutical-limited-2026-05-29-warning-letter.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_macau_union_pharmaceutical_limited_2026_05_29_warning_letter_2026,
title = {Nonprescription/OTC: FDA Warning Letter to Macau-Union Pharmaceutical Limited, 2026-05-29},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-macau-union-pharmaceutical-limited-2026-05-29-warning-letter},
note = {Accessed: July 13, 2026}
}